Fixed-dose single tablet antidiabetic combinations

C.J. Bailey, C. Day

Research output: Contribution to journalArticle


Combinations of two or more oral agents with different mechanisms of action are often used for the management of hyperglycaemia in type 2 diabetes. While these combinations have customarily been taken as separate tablets, several fixed-dose single tablet combinations are now available. These are based on bioequivalence with the separate tablets, giving similar efficacy to the separate tablets and necessitating the same cautions and contraindications that apply to each active component. Fixed-dose combinations can offer convenience, reduce the pill burden and simplify administration regimens for the patient. They increase patient adherence compared with equivalent combinations of separate tablets, and this is associated with some improvements in glycaemic control. Presently available antidiabetic fixed-dose combinations include metformin combined with a sulphonylurea, thiazolidinedione, dipeptidylpeptidase-4 inhibitor or meglitinide as well as thiazolidinedione-sulphonylurea combinations, each at a range of dosage strengths to facilitate titration. Anticipated future expansion of multiple drug regimens for diabetes management is likely to increase the use of fixed-dose single tablet combinations. © 2009 Blackwell Publishing Ltd.
Original languageEnglish
Pages (from-to)527-533
Number of pages7
JournalDiabetes, Obesity and Metabolism
Issue number6
Early online date19 Jan 2009
Publication statusPublished - Jun 2009


  • antidiabetic agents
  • bioequivalence
  • compliance
  • fixed-dose combinations
  • hypoglycaemic agents


Dive into the research topics of 'Fixed-dose single tablet antidiabetic combinations'. Together they form a unique fingerprint.

Cite this